ROME, Feb. 17, 2021 /PRNewswire/ -- The next generation Scrambler Therapy® Technology ST-5A has received marketing approval from the FDA (K201458). This new device replaces the previous two generations known as "Calmare®" and "Scrambler Therapy® Technology MC-5A" respectively, which are no longer in production.
Indications for Use (MDR 745/2017)
The specific indications for use are clinical results from scientific literature indexed and published in peer review scientific journals, based exclusively on this technology are:
In general, this device is indicated for all forms of severe chronic pain, specifically pain that does not respond to other pharmacological or non-pharmacological treatments, including opioids.
This third generation medical device is made entirely in Italy, where the scientific research that generated this technology originated. Among the most significant innovations are a modernized design, integrated compatibility dual power supply, quality guaranteed by the strict European Medical Device Regulation, and the stylistic and technological tradition of "Made in Italy".
About Delta International Service & Logistics
DIS&L is the agency created for the international development of Scrambler Therapy® Technology, and the selection of Scrambler Therapy Technology ST-5A Medical Device distributors in all international areas. DIS&L through its law firm is the only company authorized to sign international exclusive agreements, provide maintenance and client support for technical treatment training and other logistical needs.
About Scrambler Therapy®
Scrambler Therapy® scientific research and development technology has been developed in Italy by Professor Giuseppe Marineo, who is the sole owner of its intellectual property rights. The official "Scrambler Therapy"® scientific and clinical information website is:
SOURCE Delta International Services & Logistics s.r.l.
These press releases may also interest you
|